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Summary Patients with T2 grade 3 and T3 bladder cancer were randomised to be treated with radiation
alone (NO MISO) or with radiation and misonidazole (PLUS MISO). Patients in both groups initially received 40 Gy in 2 Gy fractions (5/week). Patients in the NO MISO arm received a further 20 Gy in 2 Gy fractions (5/week). Patients in the PLUS MISO arm received a further 12 Gy in 6Gy fractions (1/week). MISO was administered orally (3.0 gm-2) and intravesically (1.0 g in 35 ml of solvent) 4 h and 2 h respectively
prior to each fraction of 6 Gy.
Fifty-eight patients were randomised of whom 53 are evaluable. There is a minimum follow-up of 5 years in
the surviving patients. In the NO MISO and PLUS MISO arms, the complete response rate at cystoscopy at 6
months was 63% and 69%, the 5-year survival rate was 41% and 48% and the 5-year local control rate with bladder preservation was 46% and 36% respectively (censored for death from metastases while locally clear).
These differences are not statistically significant.
Two patients had grade 3 RTOG late bowel complications. Both patients were in the PLUS MISO arm, had
undergone salvage cystectomy and subsequently required colostomies for bowel obstruction for a 5-year late
complication rate (RTOG grade 3) of9%. In addition, two patients in the PLUS MISO arm developed wound sepsis post cystectomy.
We were not able to demonstrate improved results from the use of oral and intravesical MISO in this study. The number of patients entered are relatively low and large differences would have been required to be
detected with a power of 0.80. The use of an unconventional radiation fractionation schedule may have resulted in increased bowel morbidity in patients in the PLUS MISO arm who subsequently underwent
cystectomy.
Misonidazole (MISO) has been experimentally shown to sen-
sitise hypoxic tumour cells to irradiation both in vitro and in
vivo (Adams, 1978). The sensitiser enhancement ratio of
MISO is dependent on the tumour concentration of the drug
(Asquith et al., 1974). In clinical studies of fractionated
radiation the total amount of MISO which can be adminis-
tered is limited by the drug's neurotoxicity (peripheral neuro-
pathy) (Dische et al., 1979), and patients have been treated at
low tumour concentrations of MISO.
In patients with bladder carcinoma, high tumour concen-
trations of MISO are obtainable after intravesical administra-
tion (Awwad et al., 1983). A treatment regimen was devised
in which an initial course of conventionally fractionated
radiation was followed by two administrations of oral and
intravesical MISO plus large fractions of radiation (Abratt,
1982). The regimen was designed with the specific aim of
achieving high tumour concentrations of MISO. The aim was
to radiosensitise and sterilise clonogenic hypoxic cells persist-
ing after conventionally fractionated radiation.
The results of a pilot study of this regimen was apparently
better than that in a series of historical controls (Abratt et
al., 1983; Abratt et al., 1987). This report described the final
results of a prospective randomised study with a minimum
follow-up in surviving patients of 5 years. The initial results
of the study with the minimum follow up of 6 months have
been reported (Abratt et al., 1987).
Materials and methods
The study was conducted at Groote Schuur Hospital in Cape
Town, Provincial Hospital in Port Elizabeth, and Frere Hos-
pital in East London, between November 1981 and August
1985. Patients less than 75 years of age with T2 Grade 3 and
T3 bladder cancer were eligible for entry provided they were
available for follow-up. Informed consent was obtained from
each patient and the study was approved by the ethics
committee of the contributing centres.
All the patients had two separate target volumes deter-
mined from their bony structures and a planning cystogram. The larger treatment volume was the true pelvis from the
plane of the inferior obturator foramen to the L5 - S1 plane
and extending laterally 1 cm beyond the pelvic brim. The
coned down volume consisted of the bladder and a 1.5 cm
margin. Individual treatment plans were constructed and the
patients were treated on a cobalt-60 therapy unit at SSD of
80 cm. Randomisation between a NO MISO and a PLUS
MISO arm was by selection from a large pool of sealed
envelopes prior to therapy.
Patients in both groups received 40 Gy in 2 Gy fractions to
the whole pelvis. This was followed by radiation to the coned
down volume with or without MISO, as determined by randomisation. Patients in the NO MISO arm received a
further 20Gy in 2 Gy fractions (5/week) for a total tumour
dose of 60Gy. Patients in the PLUS MISO arm received a
further 12 Gy in 6 Gy fractions (1/week). MISO was admin-
istered orally at a dose of 3.0 gm2 and intravesically at a
dose of 1.0 g in 35 ml of solvent 4h and 2 h respectively
prior to each fraciton of 6 Gy. The bladder was emptied
immediately prior to irradiation.
A complete response at cystoscopy was determined by
inspection and palpation under anaesthetic. The urologist
assessing the patient at cystoscopy was unaware of the
methods of therapy. Cystoscopies were recommended at 3
and 6 months after therapy and thereafter at 4 to 6 monthly
intervals.
Fifty-eight patients were randomised of whom 53 are
evaluable. The five excluded patients consist of two who were
incorrectly staged and were withdrawn early in their therapy
and three who did not complete their therapy. In one of
these patients, catheterisation for MISO instillation could not
be achieved, in one further patient catheterisation was
refused and another patient declined to continue treatment
while receiving conventionally fractionated radiation. The
patient characteristics are presented in Table I.
The number of patients needed to detect an increase in
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complete response rate from 40% to 75% is 48 (one sided
test, P = 0.05 with a power of 0.80). The number of patients
needed to detect an increase in survival rate with bladder
preservation from 25% to 50% is 56 (one sided test, P = 0.05
with a power of 0.80) (Machin & Campbell, 1987). The
power of the latter test with 53 evaluable patients in this
study is 0.76 (Machin & Campbell, 1987).
Results
In the NO -MISO and PLUS MISO arms, the complete
response rate at cystoscopy at 6 months was 63% and 69%,
the 5-year survival rate was 41% and 48%, the 5-year control
rate with bladder preservation was 46% and 36% respec-
tively when the data was censored for death from metastases
while locally clear, and 36% and 31% respectively when the
data was not censored for metastases (see Table II). None of
these differences is statistically significant (chi square and
logrank).
The outcome of patients who had a complete response at
cystoscopy is shown (see Table III). In the NO MISO and
PLUS MISO arm, 64% and 56% of these patients respec-
tively remained clear of all disease at follow-up at 5 years or
until they died of intercurrent disease. The local relapse rate
was 18% and 38% respectively. The 5-year survival rate was
statistically better (log rank test) in patients with, as com-
pared to those without, a complete response for all patients
(68% and 6%, P<0.001), in the PLUS MISO arm (72%
and 0%, P<0.001) and in the NO MISO arm (63% and
10%, P<0.01).
Two patients had Grade 3 RTOG late bowel complica-
tions, that is obstruction or bleeding requiring surgery. Both
these patients who were in the PLUS MISO arm, had under-
gone salvage cystectomy and subsequently required colos-
tomies for bowel obstruction. The 5-year complication rate
(RTOG Grade 3) was 9% (life table method). In addition,
two patients in the PLUS MISO arm developed wound sepsis
post cystectomy. No patients had severe late bladder comp-
lications. There was no MISO related neurotoxicity.
Table I Patient characteristics
NO MISO PLUS MISO
Patients 26 27
Age: Mean 65 62
Range 49-75 40-74
Sex: M:F 3:1 3.5:1
Stage: T2 19% 15%
T3 81% 85%
Grade: I-II 12% 8%
III 88% 92%
Table II Results of therapy
NO MISO PLUS MISO
CR at cystoscopy at 6 month 63% 69%
5-yr survival rate (life table) 41% 48%
Local control rate:
(a) Radiation±cystectomy 51% 57%
(b) Radiation alone (preserved bladder)-
(i) Censored for metastases (locally 46% 36%
clear)
(ii) Not censored for metastases 36% 31%
TableIII Follow-up ofthe patients who achieved a complete response
at cystectomy at 6 months
NO MISO PLUS MISO
Alive and clear 7 (41%) 5 (28%)
Died ID 4 (23%) 5 (28%)
Distant metastasesa 3 (18%) 1 (6%)
Local recurrence 3 (18%) 7 (38%)
ID = Intercurrent disease. aLocally clear.
Salvage cystectomies were undertaken in 15 patients. A
complete response at cystoscopy was noted in nine of these
patients and they had undergone cystectomy for tumour
recurrence. Seven of these patients were in the PLUS MISO
arm. Their median time to recurrence was 19 months
(range = 12 to 25 months).
The 5-year survival rate in patients undergoing salvage
cystectomy was 44%. The 5-year survival rate for patients
with and without a complete response at cystoscopy at 6
months was 65.8% and 17% respectively. In the nine patients
who had a complete response and subsequently had a cystec-
tomy, five (55%) are clear, two (22%) failed with metastases
only, and two (22%) failed locally. In the six patients who
failed to have a complete response, one (17%) is alive and
clear, two (33%) failed with metastases and three (50%)
failed locally.
Discussion
A high tumour concentration of MISO was found in cystec-
tomy specimens of patients with bladder cancer after intra-
vesical MISO administration (Awwad et al., 1983). Analogous
studies in experimental mice have also resulted in high
tumour concentrations of MISO (Fathi et al., 1983). It has
also been shown in our previous study that serum levels of
MISO after oral and intravesical administration were not
higher than those after oral administration only (Abratt et
al., 1983). It therefore appeared that increased tumour radio-
sensitisation could be obtained without increased neurotoxi-
city.
MISO can, however, only be administered at this high
concentration for a part of the course of fractionated radia-
tion. It was shown in mouse studies that MISO will not
improve tumour control probabilities for the optimum radia-
tion fractionation schedule in a reoxygenating tumour,
although the drug is of benefit for all fractionation schedules
when a poorly reoxygenating tumour was studied (Fowler et
al., 1976; Sheldon & Fowler, 1978). It was hypothesised in
this study that reoxygenation might take place during the
intial course of fractionated radiation, but fail towards the
end of therapy because of the effect of radiation on the
tumour vasculature (Abratt, 1982). This hypothesis was not,
however, supported by the findings in this study, even though
the number of patients entered in the study was relatively
low. A large difference in response rate or survival rate with
bladder preservation between the two groups would be
required to be detected with a power of more than 0.80.
There are many possible reasons for failing to obtain a
gain with the use of MISO in this study. These would include
inefficient sensitisation, reoxygenation throughout the course
of radiation, a low proportion of hypoxic cells during treat-
ment, and tumour heterogeneity with intrinsic cell radioresis-
tance. In addition, the size of the large fractions in the PLUS
MISO arm was based on a clinical estimation of large bowel
tolerance. The radiation regimen used in the PLUS MISO
arm may be biologically inferior to the NO MISO arm as
regards tumour control as indicated by the linear quadratic
model (Fowler, 1989). The biological effective dose (BED) to
the coned down volume in the NO MISO (2 Gy x 10) and
MISO (6 Gy x 2) arms would be 24 Gylo and 19, 2 Gylo
respectively, assuming an alpha beta ratio of 10 for tumour
control, ignoring cell proliferation. The BED to the coned
down volume in both the NO MISO and PLUS MISO arms
would be 30 Gy4, assuming an alpha beta ratio of 4, similar
to late reacting tissue for the subpopulation of chronically
hypoxic clonagenic cells. It was assumed as well in the PLUS
MISO regimen that the persisting chronically hypoxic cells
would not be repopulating while rapid repopulation may be
taking place.
The late complication rate was closely monitored in this
study because of the use of large radiation fractions with
MISO, even though this was given to coned down volumes
only. No increased late complications were seen in patients
treated with radiation and MISO alone. In the patients who,970 R.P. ABRATT et al.
however, subsequently required a cystectomy, there does
appear to be increased morbidity. In our earlier pilot study,
the only patient with an RTOG Grade 3 late complication
also had undergone a cystectomy and subsequently required
a colostomy for bowel obstruction. It is spectulated that the
limited use of large radiation fractions in this study resulted
in patients reaching the limit of tissue tolerance and that
morbidity was precipitated by salvage cystectomy.
In the two previously reported prospective studies of radia-
tion, with or without MISO as primary treatment for bladder
cancer, MISO was used orally only (Awwad et al., 1984;
Papavasilou et al., 1983). In neither study was there a statis-
tically significant difference between the tumour response rate
or recurrence-free survival in the patients treated with or
without MISO.
Radical irradiation with surveillance cystoscopy and sal-
vage cystectomy can be an effective form of therapy in
patients with bladder cancer with 25% to 50% of patients
being locally disease-free with preserved bladders at follow-
up. Factors which predict a favourable outcome have been
discussed (Shipley et al., 1985). We have not been able to
show additional benefit from oral and intravesical MISO in
this prospective randomised trial. Improved sensitisers have
been developed for clinical investigation. Their optimal use
required a better understanding of the pattern of tumour
reoxygenation in clinical radiotherapy.
The authors wish to thank Roche for the provision of Misonidazole
and Mrs D. Godley for the typing of the manuscript.
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